TherapeuticsMD Inc (TXMD) - Net Assets
Based on the latest financial reports, TherapeuticsMD Inc (TXMD) has net assets worth $26.88 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($37.66 Million) and total liabilities ($10.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is TherapeuticsMD Inc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.88 Million |
| % of Total Assets | 71.37% |
| Annual Growth Rate | 14.37% |
| 5-Year Change | N/A |
| 10-Year Change | -78.92% |
| Growth Volatility | 439.27 |
TherapeuticsMD Inc - Net Assets Trend (1994–2025)
This chart illustrates how TherapeuticsMD Inc's net assets have evolved over time, based on quarterly financial data. See TXMD defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for TherapeuticsMD Inc (1994–2025)
The table below shows the annual net assets of TherapeuticsMD Inc from 1994 to 2025. For live valuation and market cap data, see TherapeuticsMD Inc (TXMD) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $26.88 Million | -1.80% |
| 2024-12-31 | $27.37 Million | -6.55% |
| 2023-12-31 | $29.29 Million | -16.66% |
| 2022-12-31 | $35.14 Million | +137.54% |
| 2021-12-31 | $-93.62 Million | +24.50% |
| 2020-12-31 | $-124.00 Million | -1447.67% |
| 2019-12-31 | $9.20 Million | -90.57% |
| 2018-12-31 | $97.52 Million | -24.93% |
| 2017-12-31 | $129.91 Million | +1.90% |
| 2016-12-31 | $127.49 Million | +102.16% |
| 2015-12-31 | $63.06 Million | +30.33% |
| 2014-12-31 | $48.39 Million | -11.53% |
| 2013-12-31 | $54.70 Million | +3916.71% |
| 2012-12-31 | $-1.43 Million | +16.28% |
| 2011-12-31 | $-1.71 Million | -88.62% |
| 2010-12-31 | $-907.55K | -191.77% |
| 2009-12-31 | $-311.05K | -1763.65% |
| 2008-12-31 | $18.70K | -95.52% |
| 2007-12-31 | $417.54K | -75.25% |
| 2006-12-31 | $1.69 Million | +28.38% |
| 2005-12-31 | $1.31 Million | +25.00% |
| 2004-12-31 | $1.05 Million | +21.40% |
| 2003-12-31 | $866.11K | +17.61% |
| 2002-12-31 | $736.41K | +9.57% |
| 2001-12-31 | $672.09K | +9.82% |
| 2000-12-31 | $611.97K | +27.40% |
| 1999-12-31 | $480.35K | +4.85% |
| 1998-12-31 | $458.12K | -7.99% |
| 1997-12-31 | $497.89K | -2.54% |
| 1996-12-31 | $510.88K | +15.97% |
| 1995-12-31 | $440.53K | +5.17% |
| 1994-12-31 | $418.86K | -- |
Equity Component Analysis
This analysis shows how different components contribute to TherapeuticsMD Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 95191476500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.04% |
| Other Components | $979.26 Million | 3643.61% |
| Total Equity | $26.88 Million | 100.00% |
TherapeuticsMD Inc Competitors by Market Cap
The table below lists competitors of TherapeuticsMD Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
111 Inc
NASDAQ:YI
|
$22.92 Million |
|
Murano Global Investments PLC Ordinary Shares
NASDAQ:MRNO
|
$22.92 Million |
|
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
|
$22.93 Million |
|
ESS Tech Inc
NYSE:GWH
|
$22.93 Million |
|
Andromeda Metals Ltd
AU:ADN
|
$22.90 Million |
|
GWR Group Ltd
AU:GWR
|
$22.90 Million |
|
Blue Star Helium Ltd
AU:BNL
|
$22.90 Million |
|
Hamama
TA:HMAM
|
$22.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TherapeuticsMD Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 27,370,000 to 26,876,000, a change of -494,000 (-1.8%).
- Net loss of 569,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-569.00K | -2.12% |
| Other Changes | $75.00K | +0.28% |
| Total Change | $- | -1.80% |
Book Value vs Market Value Analysis
This analysis compares TherapeuticsMD Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.67x to 0.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $1.36 | $2.27 | x |
| 1995-12-31 | $1.43 | $2.27 | x |
| 1996-12-31 | $1.65 | $2.27 | x |
| 1997-12-31 | $1.61 | $2.27 | x |
| 1998-12-31 | $1.48 | $2.27 | x |
| 1999-12-31 | $1.52 | $2.27 | x |
| 2000-12-31 | $1.94 | $2.27 | x |
| 2001-12-31 | $2.13 | $2.27 | x |
| 2002-12-31 | $2.17 | $2.27 | x |
| 2003-12-31 | $2.55 | $2.27 | x |
| 2004-12-31 | $3.14 | $2.27 | x |
| 2005-12-31 | $3.98 | $2.27 | x |
| 2006-12-31 | $5.11 | $2.27 | x |
| 2007-12-31 | $1.35 | $2.27 | x |
| 2008-12-31 | $0.03 | $2.27 | x |
| 2009-12-31 | $-0.21 | $2.27 | x |
| 2010-12-31 | $-0.12 | $2.27 | x |
| 2011-12-31 | $-1.37 | $2.27 | x |
| 2012-12-31 | $-0.78 | $2.27 | x |
| 2013-12-31 | $21.44 | $2.27 | x |
| 2014-12-31 | $16.16 | $2.27 | x |
| 2015-12-31 | $18.21 | $2.27 | x |
| 2016-12-31 | $32.51 | $2.27 | x |
| 2017-12-31 | $31.60 | $2.27 | x |
| 2018-12-31 | $21.67 | $2.27 | x |
| 2019-12-31 | $1.87 | $2.27 | x |
| 2020-12-31 | $-22.49 | $2.27 | x |
| 2021-12-31 | $-11.76 | $2.27 | x |
| 2022-12-31 | $3.89 | $2.27 | x |
| 2023-12-31 | $2.80 | $2.27 | x |
| 2024-12-31 | $2.37 | $2.27 | x |
| 2025-12-31 | $2.32 | $2.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TherapeuticsMD Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.83%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.40x
- Recent ROE (-2.12%) is above the historical average (-129.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 8.16% | 17.37% | 0.46x | 1.03x | $-7.70K |
| 1995 | 7.15% | 16.09% | 0.39x | 1.15x | $-12.54K |
| 1996 | 14.44% | 30.24% | 0.47x | 1.01x | $22.70K |
| 1997 | -2.56% | -6.60% | 0.38x | 1.01x | $-62.53K |
| 1998 | -3.40% | -8.03% | 0.38x | 1.11x | $-61.39K |
| 1999 | 2.59% | 5.80% | 0.43x | 1.04x | $-35.61K |
| 2000 | 21.52% | 35.78% | 0.59x | 1.03x | $70.47K |
| 2001 | 9.16% | 18.50% | 0.48x | 1.03x | $-5.67K |
| 2002 | 13.43% | 34.51% | 0.38x | 1.02x | $25.27K |
| 2003 | 10.87% | 21.51% | 0.49x | 1.04x | $7.50K |
| 2004 | 13.52% | 22.85% | 0.57x | 1.04x | $36.97K |
| 2005 | 22.06% | 31.02% | 0.52x | 1.38x | $158.46K |
| 2006 | 22.11% | 37.11% | 0.54x | 1.11x | $204.28K |
| 2007 | 40.84% | 0.00% | 0.00x | 1.19x | $128.79K |
| 2008 | -2115.60% | 0.00% | 0.00x | 2.91x | $-397.42K |
| 2009 | 0.00% | -15654.66% | 0.01x | 0.00x | $-1.62 Million |
| 2010 | 0.00% | -1442.18% | 0.10x | 0.00x | $-604.62K |
| 2011 | 0.00% | -618.40% | 1.45x | 0.00x | $-12.74 Million |
| 2012 | 0.00% | -919.86% | 0.66x | 0.00x | $-34.98 Million |
| 2013 | -51.96% | -323.84% | 0.14x | 1.13x | $-33.89 Million |
| 2014 | -112.04% | -360.82% | 0.25x | 1.22x | $-59.06 Million |
| 2015 | -134.91% | -422.37% | 0.27x | 1.17x | $-91.38 Million |
| 2016 | -70.50% | -464.32% | 0.14x | 1.12x | $-102.62 Million |
| 2017 | -59.21% | -458.50% | 0.12x | 1.10x | $-89.92 Million |
| 2018 | -135.98% | -823.74% | 0.08x | 2.17x | $-142.37 Million |
| 2019 | -1914.39% | -354.79% | 0.19x | 28.91x | $-177.07 Million |
| 2020 | 0.00% | -282.90% | 0.36x | 0.00x | $-171.12 Million |
| 2021 | 0.00% | -6700.93% | 0.02x | 0.00x | $-163.05 Million |
| 2022 | 318.69% | 160.08% | 0.77x | 2.57x | $108.48 Million |
| 2023 | -35.09% | -789.40% | 0.03x | 1.48x | $-13.21 Million |
| 2024 | -7.97% | -123.85% | 0.05x | 1.42x | $-4.92 Million |
| 2025 | -2.12% | -18.83% | 0.08x | 1.40x | $-3.26 Million |
Industry Comparison
This section compares TherapeuticsMD Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $379,169,986
- Average return on equity (ROE) among peers: -14.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TherapeuticsMD Inc (TXMD) | $26.88 Million | 8.16% | 0.40x | $22.92 Million |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $172.65 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $273.24 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.42 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.19 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $37.89 Million | 15.55% | 0.65x | $189.34 Million |
| ANI Pharmaceuticals Inc (ANIP) | $197.26 Million | 7.85% | 1.18x | $1.80 Billion |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more